Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia

Hui Li, Shi-Gui Yang, Li Gu, Yao Zhang, Xi-Xin Yan, Zong-An Liang, Wei Zhang, Hong-Yu Jia, Wei Chen, Meng Liu, Kai-Jiang Yu, Chun-Xue Xue, Ke Hu, Qi Zou, Lan-Juan Li, Bin Cao, Chen Wang, National Influenza A(H1N1)pdm09 Clinical Investigation Group of China, Hui Li, Shi-Gui Yang, Li Gu, Yao Zhang, Xi-Xin Yan, Zong-An Liang, Wei Zhang, Hong-Yu Jia, Wei Chen, Meng Liu, Kai-Jiang Yu, Chun-Xue Xue, Ke Hu, Qi Zou, Lan-Juan Li, Bin Cao, Chen Wang, National Influenza A(H1N1)pdm09 Clinical Investigation Group of China

Abstract

Background: The effect of corticosteroids on influenza A(H1N1)pdm09 viral pneumonia patients remains controversial, and the impact of dosage has never been studied.

Methods: Using data of hospitalized adolescent and adult patients with influenza A(H1N1)pdm09 viral pneumonia, prospectively collected from 407 hospitals in mainland China, the effects of low-to-moderate-dose (25-150 mg d-1 ) and high-dose (>150 mg d-1 ) corticosteroids on 30-day mortality, 60-day mortality, and nosocomial infection were assessed with multivariate Cox regression and propensity score-matched case-control analysis.

Results: In total, 2141 patients (median age: 34 years; morality rate: 15.9%) were included. Among them, 1160 (54.2%) had PaO2 /FiO2 <300 mm Hg on admission, and 1055 (49.3%) received corticosteroids therapy. Corticosteroids, without consideration of dose, did not influence either 30-day or 60-day mortality. Further analysis revealed that, as compared with the no-corticosteroid group, low-to-moderate-dose corticosteroids were related to reduced 30-day mortality (adjusted hazard ratio [aHR] 0.64 [95% CI 0.43-0.96, P=.033]). In the subgroup analysis among patients with PaO2 /FiO2 <300 mm Hg, low-to-moderate-dose corticosteroid treatment significantly reduced both 30-day mortality (aHR 0.49 [95% CI 0.32-0.77]) and 60-day mortality (aHR 0.51 [95% CI 0.33-0.78]), while high-dose corticosteroid therapy yielded no difference. For patients with PaO2 /FiO2 ≥300 mm Hg, corticosteroids (irrespective of dose) showed no benefit and even increased 60-day mortality (aHR 3.02 [95% CI 1.06-8.58]). Results were similar in the propensity model analysis.

Conclusions: Low-to-moderate-dose corticosteroids might reduce mortality of influenza A(H1N1)pdm09 viral pneumonia patients with PaO2 /FiO2 <300 mm Hg. Mild patients with PaO2 /FiO2 ≥300 mm Hg could not benefit from corticosteroid therapy.

Keywords: corticosteroids; influenza A(H1N1)pdm09 virus; mortality; pneumonia.

© 2017 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Study flow diagram
Figure 2
Figure 2
Kaplan‐Meier survival curves for matched patients treated with low‐to‐moderate‐dose corticosteroids or with no corticosteroids (control), censored at 30 d. A, Including all the patients (n=530, log‐rank chi‐squared=10.48, P=.001), the 30‐day mortality in the low‐to‐moderate dose corticosteroid group and control group was 6.8% (18/265) and 14.7% (39/265), respectively. B, Including patients with PaO2/FiO2 <300 mm Hg (n=351, log‐rank chi‐squared=13.24, P<.001), the 30‐day mortality in the low‐to‐moderate‐dose corticosteroid group and control group was 8.1% (14/173) and 20.2% (36/178), respectively. C, Including patients with PaO2/FiO2 ≥300 mm Hg (n=179, log‐rank chi‐squared=0.17, P=.68), the 30‐day mortality in the low‐to‐moderate‐dose corticosteroid group and control group was 4.3% (4/92) and 3.4% (3/87), respectively
Figure 3
Figure 3
Kaplan‐Meier survival curves for matched patients treated with high‐dose corticosteroids or with no corticosteroids (control), censored at 30 d. A, Including all the patients (n=296, log‐rank chi‐squared=1.06, P=.30), the 30‐day mortality in the high‐dose corticosteroid group and control group was 17.6% (26/148) and 19.6% (29/148), respectively. B, Including patients with PaO2/FiO2 <300 mm Hg (n=256, log‐rank chi‐squared=1.33, P=.25), the 30‐day mortality in the high‐dose corticosteroids group and control group was 19.7% (25/127) and 22.5% (29/129), respectively

References

    1. Yu X, Zhang X, Zhao B, et al. Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL‐10 and IL‐6. PLoS ONE. 2011;6:e28680.
    1. Yang SQ, Qu JX, Wang C, Yu XM, Liu YM, Cao B. Influenza pneumonia among adolescents and adults: a concurrent comparison between influenza A (H1N1) pdm09 and A (H3N2) in the post‐pandemic period. Clin Respir J. 2014;8:185‐191.
    1. Zhao Y, Zhang YH, Denney L, et al. High levels of virus‐specific CD4+ T cells predict severe pandemic influenza A virus infection. Am J Respir Crit Care Med. 2012;186:1292‐1297.
    1. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med. 2010;181:72‐79.
    1. Shieh WJ, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol. 2010;177:166‐175.
    1. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302:1896‐1902.
    1. Li C, Yang P, Zhang Y, et al. Corticosteroid treatment ameliorates acute lung injury induced by 2009 swine origin influenza A (H1N1) virus in mice. PLoS ONE. 2012;7:e44110.
    1. Ottolini M, Blanco J, Porter D, Peterson L, Curtis S, Prince G. Combination anti‐inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol. 2003;36:290‐294.
    1. Quispe‐Laime AM, Bracco JD, Barberio PA, et al. H1N1 influenza A virus‐associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med. 2010;36:33‐41.
    1. Lee KY, Rhim JW, Kang JH. Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: a need for early immune‐modulators for severe cases. Med Hypotheses. 2011;76:64‐69.
    1. Martin‐Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 2011;37:272‐283.
    1. Diaz E, Martin‐Loeches I, Canadell L, et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect 2012;64:311‐318.
    1. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med. 2011;183:1207‐1214.
    1. Brun‐Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183:1200‐1206.
    1. Annane D. Pro: the illegitimate crusade against corticosteroids for severe H1N1 pneumonia. Am J Respir Crit Care Med. 2011;183:1125‐1126.
    1. Matthay MA, Liu KD. Con: corticosteroids are not indicated for treatment of acute lung injury from H1N1 viral pneumonia. Am J Respir Crit Care Med. 2011;183:1127‐1128.
    1. Delaney JW, Pinto R, Long J, et al. The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)‐related critical illness. Crit Care. 2016;20:75.
    1. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492‐500.
    1. Giannella M, Alonso M, Garcia de Viedma D, et al. Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients. Clin Microbiol Infect 2011;17:1160‐1165.
    1. World Health Organization . (2009) Clinical management of human infection with pandemic (H1N1) 2009: revised guidance, November 2009. Accessed at: . Date last updated: November 2009. Accessed: January, 2016.
    1. Rodrigo C, Leonardi‐Bee J, Nguyen‐Van‐Tam JS, Lim WS. Effect of Corticosteroid Therapy on Influenza‐Related Mortality: A Systematic Review and Meta‐analysis. J Infect Dis. 2015;212:183‐194.
    1. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community‐acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313:677‐686.
    1. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community‐acquired pneumonia: a multicentre, double‐blind, randomised, placebo‐controlled trial. Lancet. 2015;385:1511‐1518.
    1. Tagami T, Matsui H, Horiguchi H, Fushimi K, Yasunaga H. Low‐dose corticosteroid use and mortality in severe community‐acquired pneumonia patients. Eur Respir J. 2015;45:463‐472.
    1. Li F, Chen G, Wang J, Liu H, Wu J. A case‐control study on risk factors associated with death in pregnant women with severe pandemic H1N1 infection. BMJ Open 2012;2:1‐6.
    1. Linko R, Pettila V, Ruokonen E, et al. Corticosteroid therapy in intensive care unit patients with PCR‐confirmed influenza A(H1N1) infection in Finland. Acta Anaesthesiol Scand. 2011;55:971‐979.
    1. Mady A, Ramadan OS, Yousef A, Mandourah Y, Amr AA, Kherallah M. Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia. J Infect Public Health. 2012;5:52‐56.
    1. Sertogullarindan B, Ozbay B, Gunini H, et al. Clinical and prognostic features of patients with pandemic 2009 influenza A (H1N1) virus in the intensive care unit. Afr Health Sci. 2011;11:163‐170.
    1. Viasus D, Pano‐Pardo JR, Cordero E, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect. 2011;62:193‐199.
    1. Xi X, Xu Y, Jiang L, Li A, Duan J, Du B. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis. 2010;10:256.
    1. Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N, Meade M. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: a meta‐analysis of randomized controlled trials. J Crit Care. 2010;25:420‐435.
    1. Tang BM, Craig JC, Eslick GD, Seppelt I, McLean AS. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta‐analysis. Crit Care Med. 2009;37:1594‐1603.
    1. Wang C, Yu H, Horby PW, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis. 2014;58:1095‐1103.
    1. Yang SG, Cao B, Liang LR, et al. Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS ONE. 2012;7:e29652.
    1. Lee N, Leo YS, Cao B, et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. Eur Respir J. 2015;45:1642‐1652.
    1. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813‐1821.
    1. Shi SJ, Li H, Liu M, et al. Mortality prediction to hospitalized patients with influenza pneumonia: PO/FiO combined lymphocyte count is the answer. Clin Respir J. 2017;11:352‐360.
    1. Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16:e321‐e331.
    1. Pillai PS, Molony RD, Martinod K, et al. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. Science. 2016;352:463‐466.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera